Impact of treatment-related cardiac toxicity on lymphoma survivors: An institutional approach for risk reduction and management

Clinical Journal of Oncology Nursing

Volumn 14, Issue 4, 2010, Pages 505-507

  Walsh, Michele C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; HEART DISEASE; HUMAN; LYMPHOMA; PRACTICE GUIDELINE; RADIOTHERAPY; RISK FACTOR;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HUMANS; LYMPHOMA; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY; RISK FACTORS;

EID: 79952110327     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.505-507     Document Type: Article

References (24)

1. Adams, M.J., Lipsitz, S.R., Colan, S.D., Tarbell, N.J., Treves, S.T., Diller, L., Lipshultz, S.E. (2004). Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. Journal of Clinical Oncology, 22, 3139-3148. doi: 10.1200/JCO.2004.09.109
2. Ali, M.K. (1992). The natural history of anthracycline cardiotoxicity in children. In F. Muggia (Ed.), Cancer treatment and the patient (pp. 246-255). Baltimore, MD: Johns Hopkins University.
3. Armitage, J.O., & Potter, J.F. (1984). Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. Journal of the American Geriatrics Society, 32, 269-273.
4. Bedford Laboratories. (2002). Adriamycin® (doxorubicin hydrochloride injection) [Package insert]. Bedford, OH: Author.
5. Chen, A.B., Punglia, R.S., Kuntz, K.M., Mauch, P.M., & Ng, A.K. (2009). Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. Journal of Clinical Oncology, 27, 5383-5389. doi: 10.1200/JCO.2009.22.8460
6. Earle, C.C. (2006). Failing to plan is planning to fail: Improving the quality of care with survivorship care plans. Journal of Clinical Oncology, 24, 5112-5116. doi: 10.1200/JCO.2006.06.5284
7. Galderisi, M., Marra, F., Esposito, R., Lomoriello, V.S., Pardo, M., & de Divitiis, O. (2007). Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography. Cardiovascular Ultrasound, 5, 4. doi: 10.1186/1476-7120-5-4
8. Genovesi, E.A., Colivicchi, F., Malvezzi Caracciolo, M., & Riccio, C. (2009). Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure. Monaldi Archives for Chest Disease, 72, 18-22.
9. Heidenreich, P.A., Hancock, S.L., Lee, B.K., Mariscal, C.S., & Schnittger, I. (2003). Asymptomatic cardiac disease following mediastinal irradiation. Journal of the American College of Cardiology, 42, 743-749. doi: 10.1016/S0735-1097(03)00759-9
10. Henry-Amar, M., & Somers, R. (1990). Survival outcome after Hodgkin's disease: A report from the international data base on Hodgkin's disease. Seminars in Oncology, 17, 758-768.
11. Hequet, O., Le, Q.H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Coiffier, B. (2004). Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. Journal of Clinical Oncology, 22, 1864-1871. doi: 10.1200/JCO.2004.06.033
12. Hewitt, M., & Ganz, P. (2007). Implementing cancer survivorship care planning: Workshop summary. Washington, DC: National Academies Press.
13. Keefe, D.L. (2001). Anthracycline-induced cardiomyopathy. Seminars in Oncology, 28(Suppl. 12), 2-7.
14. Mauch, P.M., Kalish, L.A., Marcus, K.C., Shulman, L.N., Krill, E., Tarbell, N.J., Coleman, C.N. (1995). Long-term survival in Hogkin's disease: Relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer Journal From Scientific American, 1, 33.
15. Morgan, M. (2009). Cancer survivorship: History, quality of life issues, and the evolving multidisciplinary approach to implementation of cancer survivorship care plans. Oncology Nursing Forum, 36, 429-436. doi: 10.1188/09.ONF.429-436
16. Myers, C. (1988). Role of iron in anthracycline action. In M. Hacker (Ed.), Organ directed toxicities of anticancer drugs (pp. 17-30). Boston, MA: Kluwer Academies Publishers.
17. Myrehaug, S., Pintilie, M., Tsang, R., Mackenzie, R., Crump, M., Chen, Z., Hodgson, D.C. (2008). Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leukemia and Lymphoma, 49, 1433-1435. doi: 10.1080/10428190802140873
18. National Comprehensive Cancer Network. (2009). NCCN Clinical Practice Guidelines in Oncology™: Screening and management of hyperlipidemia. Retrieved from http://www.nccn.org/professional/physician_gls/default.asp
19. Novaro, G.M., Tiong, I.Y., Pearce, G.L., Lauer, M.S., Sprecher, D.I., & Griffin, B.P. (2001). Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation, 104, 2205-2209. doi: 10.1161/hc4301.098249
20. Orzan, F., Brusca, A., Conte, M.R., Presbitero, P., & Figliomeni, M.C. (1993). Severe coronary artery disease after radiation therapy of the chest and mediastinum: Clinical presentation and treatment. British Heart Journal, 69, 496-500. doi: 10.1136/hrt.69.6.496
21. Singal, P.K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. New England Journal of Medicine, 339, 900-905. doi: 10.1056/NEJM199809243391307
22. Veinot, J.P., & Edwards, W.D. (1996). Pathology of radiation-induced heart disease: A surgical and autopsy study of 27 cases. Human Pathology, 27, 766-773. doi: 10.1016/S0046-8177(96)90447-5
23. Wettergren, L., Bjorkholmn, M., Axdorph, U., & Langius-Eklof, A. (2004). Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. Quality of Life Research, 13, 1369-1379. doi: 10.1023/B:QURE.0000040790.43372.69
24. Wild, D.M., & Kukin, M. (2007). Beta-blockers to prevent symptomatic heart failure in patients with stage A and B heart failure. Current Heart Failure Reports, 4, 99-102. doi: 10.1007/s11897-007-0007-4